Patients with Parkinson disease (PD) who use inappropriate antipsychotics may be at an increased risk for pneumonia compared with patients with PD who use more appropriate atypical antipsychotics.
The FDA has approved the supplemental NDA for Baxdela for the treatment of community acquired bacterial pneumonia in adult patients.
Pneumonia is one of the leading causes of neonatal respiratory distress, and is most commonly acquired at birth.
Thirty-day readmission following hospitalization for pneumonia is common in patients with underlying comorbidities such as COPD, kidney and heart diseases, and dementia.
A typical usual interstitial pneumonia pattern was the predominant radiologic pattern seen in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.
Delafloxacin may provide a feasible alternative antibiotic monotherapy option for treating patients with community-acquired bacterial pneumonia (CABP) who have renal impairment in both inpatient and outpatient settings.
Children with neurologic impairment had lower rates of recurrent severe pneumonia if they practiced dental care as a preventive measure.
The ATS and IDSA have presented recommendations for the diagnosis and management of community-acquired pneumonia.
Lefamulin appears to be noninferior in safety and efficacy compared with moxifloxicin in the treatment of community-acquired bacterial pneumonia.
A new scoring system for Drug Resistance in Pneumonia (DRIP) has demonstrated efficacy in improving pneumonia-related prescription trends, including a significant drop in broad-spectrum antibiotic prescriptions.
